Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has reported Cash from Financing Activities for 13 consecutive years, with $394.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash from Financing Activities rose 13285.13% year-over-year to $394.2 million; the TTM figure through Dec 2025 stood at $478.0 million (up 19.8% YoY), while the FY2025 annual figure was $478.0 million, up 19.8% from the prior year.
• Cash from Financing Activities rose to $394.2 million in Q4 2025 per RARE's latest filing, from $2000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $491.9 million in Q3 2022 and bottomed at -$722000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $94.2 million across 5 years, with a median of $11.9 million in 2021.
• On a YoY basis, Cash from Financing Activities climbed as much as 17459.4% in 2023 and fell as far as 144.79% in 2023.
• Ultragenyx Pharmaceutical's Cash from Financing Activities stood at $85.7 million in 2021, then tumbled by 97.8% to $1.9 million in 2022, then surged by 17459.4% to $330.5 million in 2023, then sank by 99.11% to $2.9 million in 2024, then surged by 13285.13% to $394.2 million in 2025.
• Business Quant data shows RARE's Cash from Financing Activities at $394.2 million in Q4 2025, $2000.0 in Q3 2025, and $83.6 million in Q2 2025.